InfluenzaPhase 3NCT00128167
Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age
A Phase 3 study testing Liquid CAIV-T in people with Influenza, run by MedImmune LLC at 161 sites in 8 countries.
Trial summary
The primary objective of this study is to estimate the relative efficacy and assess the safety of CAIV-T compared to TIV. Read more about this study
- Who is it for?
- Ages 6 to 59 monthsHealthy volunteers can take part
- Conditions the study is for
- Influenza
- What is being tested?
- Liquid CAIV-T
- How many people
- 8,500 participants
- Where
- 161 sitesin 8 countries
- Study dates
- Oct 2004to Dec 2005
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 59 months
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Age 6-59 months of age (not yet reached their 5th birthday)
- Parent or guardian available by telephone
- Available for illness visits at clinic or at home during the influenza surveillance period
- Written informed consent (and Health Insurance Portability and Accountability Act [HIPAA] authorization for U.S. Participants) obtained from the participant's parent or legal guardian and
- Ability of the parent/guardian to understand and comply with the requirements of the protocol
Who cannot join
- History of hypersensitivity to any component of CAIV-T or inactivated influenza vaccine, including egg or egg protein
- History of hypersensitivity to gentamicin
- Any known immunosuppressive condition or immune deficiency disease (including HIV infection), or ongoing receipt of any immunosuppressive therapy
- History of Guillain-Barre syndrome
- Medically-diagnosed wheezing, bronchodilator use, or steroid use (systemic or inhaled) within the previous 42 days by parent report or chart review (e.g., children with recent persistent asthma are excluded), or history of severe asthma
- Acute febrile (>100.0 degrees F or >37.8 degrees C oral or equivalent) illness or acute respiratory illness, including sore throat, within three days prior to enrollment
Show all 15Show fewer
- Receipt of an investigational product within 30 days prior to enrollment or expected receipt during this study
- Use of aspirin or salicylate-containing products 30 days prior to enrollment or expected receipt during this study
- Use of anti-influenza medications (including amantadine, rimantadine, oseltamivir, and zanamivir) within 14 days prior to enrollment or expected receipt during this study
- Receipt of any blood product within 90 days prior to vaccination or expected receipt during this study
- Administration of any live virus vaccine within 30 days prior to enrollment, or if receipt of another live virus vaccine is expected within 30 days of any study vaccination
- Administration of any inactivated vaccine within 14 days prior to enrollment or if receipt of another inactivated vaccine is expected within 14 days prior to enrollment or if receipt of another inactivated vaccine is expected within 14 days of any study vaccination
- Close contact who is severely immunocompromised (e.g., transplant recipient)
- Family member or household contact who is an employee of the research center or otherwise involved with the conduct of the study and
- Any condition that, in the opinion of the investigator, might interfere with the interpretation or evaluation of the vaccines.
Trial locations and contacts
161 sites in 8 countries.
161 sites in 8 countries
United States107 sites
Friendly Care Medical Group
Anaheim, California, 92805
Emory University School of Medicine, Dept of Pediatrics, Div of Infectious Diseases
Atlanta, Georgia, 30322
Wells Branch Medical Center
Austin, Texas, 78728
Kentucky Pediatrics/Adult Research Inc.
Bardstown, Kentucky, 40004
East Bay Pediatrics
Barrington, Rhode Island, 02806
Impact Clinical Trials
Beverly Hills, California, 90211
United Medical Associates
Binghamton, New York, 13901
Odyssey Research
Bismarck, North Dakota, 58501
Clinical Trials Management, LLC/The Pediatric Clinic
Bogalusa, Louisiana, 70427
Boone Pediatric Center
Boone, North Carolina, 28607
Boston University Medical Center
Boston, Massachusetts, 02118
Bozeman Urgent Care Center
Bozeman, Montana, 59715
Barbara Dzierzek/PharmaTrials, Inc.
Brooklyn, New York, 11222
PI-Coor Clinical Research, LLC
Burke, Virginia, 22015
University of North Carolina Department of Pediatrics
Chapel Hill, North Carolina, 79599
Medical University of South Carolina
Charleston, South Carolina, 29425
Respiratory Disease Study Unit
Charlottesville, Virginia, 22901
Rush University Medical Center/University Consultatnts in Allergy and Immunology
Chicago, Illinois, 60612
Children's Memorial Hospital
Chicago, Illinois, 60641
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229
Pediatric Associates of Mt. Carmel
Cincinnati, Ohio, 45245
Sadler Clinic/Healthsouth Clinical Research
Conroe, Texas, 77304
Health Sciences Research Center
Cortland, New York, 13045
Omega Medical Research
Cranston, Rhode Island, 02920
Pediatric Allergy/Immunology Associates, PA
Dallas, Texas, 75230
Odyssey Research
Dearborn, Michigan, 48126
Chidren's Hospital of Michigan
Detroit, Michigan, 48201
Medsouth Healthcare
Dyersburg, Tennessee, 38024
Endwell Family Physicians
Endwell, New York, 13760
Dakota Clinic/Innovis Health
Fargo, North Dakota, 58104
Family Medical Center
Foothill Ranch, California, 92610
Healthfirst Medical Group
Fort Worth, Texas, 76135
Edinger Mecial Group
Fountain Valley, California, 92708-7504
Fresno Childrens Medical Group, Inc.
Fresno, California, 93720
Henderson Pediatrics
Henderson, Nevada, 89015
Clinical Research Consultants, Inc
Hoover, Alabama, 35216
Med-Pro Research Inc.
Houston, Texas, 77004
Ohio Pediatrics
Huber Heights, Ohio, 45424
Univeristy Pediatrics
Huntington, West Virginia, 25701
Scott and White/Pediatric Clinic
Killeen, Texas, 76451
Holston Medical Group Pediatrics
Kingsport, Tennessee, 37660
Rd Clinical Research Inc.
Lake Jackson, Texas, 77566
Clinical Research Center of Nevada
Las Vegas, Nevada, 89104
Purcell Clinic
Laurinburg, North Carolina, 28352
Wee Care Pediatrics
Layton, Utah, 84041
Little Rock Allergy and Asthma Clinical
Little Rock, Arkansas, 72205
Heathcare Partners Medical Group
Los Angeles, California, 90015
University Child Health Specialists, PCTU
Louisville, Kentucky, 40202
Pediatrics and Adolescent Medicine, P.A.
Marietta, Georgia, 30062
Medical Parameters
Martinez, Georgia, 30907
Clinical Research Care & Resource Center, Inc
Miami, Florida, 33156
Winthrop University Hospital
Mineola, New York, 11501
Monroe Medical Foundation
Monroe, Wisconsin, 53566
Murfressboro Medical Clinic
Murfreesboro, Tennessee, 37130
Cottonwood Pediatrics
Murray, Utah, 84107
Clarkstown Pediatric Associates
Nanuet, New York, 10954
Pediatric Clincal Research Office
Nashville, Tennessee, 37232-2573
Central Texas Health Research
New Braunfels, Texas, 78130
Dolby Providers LLC
New Orleans, Louisiana, 70128
Suncoast Clinical Research
New Port Richey, Florida, 34652
CPMC Research Pharmacy
New York, New York, 10032
Health Research of Hampton Roads, Inc
Newport News, Virginia, 23606
Center for Pediatric Research
Norfolk, Virginia, 23510
Sneeze, Wheeze, & Itch Associates, LLC
Normal, Illinois, 61761
Norwich Pediatric Group, PC
Norwich, Connecticut, 06360
Kaiser Permanente Vaccine Study Center
Oakland, California, 94612
Bear Care Pediatrics
Ogden, Utah, 84450
Grand Prairie Pediatric and Allergy Clinic
Oklahoma City, Oklahoma, 73132
Creighton/UNMC Pediatric Infectious Disease
Omaha, Nebraska, 68131
Meridian Clinical Research, LLC
Omaha, Nebraska, 68134
Pediatric Research Center of South Florida
Palm Beach Gardens, Florida, 33410
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15123
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
Primary Physicians Research Inc.
Pittsburgh, Pennsylvania, 15241-3100
Alpine Pediatrics
Pleasant Grove, Utah, 84062
Utah Valley Pediatrics
Provo, Utah, 84604
North Carolina Clinical Research
Raleigh, North Carolina, 27607
VCU Campus Children's Pavilion/Pediatric Clinical Trials Office
Richmond, Virginia, 23219
Elmwood Pediatrics
Rochester, New York, 14620
University Rochester Medical Center
Rochester, New York, 14642
PRA Trials
Rolling Hills Estates, California, 90274
J. Lewis Research Inc.
Salt Lake City, Utah, 84109
J. Lewis Research, Inc.
Salt Lake City, Utah, 84121
Benchmark Research
San Angelo, Texas, 76904
Quality Assurance Research Center
San Antonio, Texas, 78207
Benchmark Research
San Francisco, California, 94102
Heart of America Research Institute
Shawnee Mission, Kansas, 66216
South Bend Clinic
South Bend, Indiana, 46617
Families First Pediatrics
South Jordan, Utah, 84095
Center for Vaccine Development
St Louis, Missouri, 63110
Summit Pediatric Pulmonary
Summit, New Jersey, 07901
Sylva Pediatrics Associates
Sylva, North Carolina, 28779
Northeast Pediatrics and Adolescent Medicine
Syracuse, New York, 13210
Jacobi Medical Center
The Bronx, New York, 10461
Montefiore Medical Center
The Bronx, New York, 10467
Heart of America Research Institute-Topeka
Topeka, Kansas, 66614
Hillcrest Medical Group/Utica Park Clinic
Tulsa, Oklahoma, 74104
University of Alabama
Tuscaloosa, Alabama, 35401
Shelly Senders and Associates
University Heights, Ohio, 44118
Asthma & Allergy Research Associates
Upland, Pennsylvania, 19013
Advanced Pediatrics
Vienna, Virginia, 22180-4224
Georgetown University Medical Center
Washington D.C., District of Columbia, 20057
Northridge Brown Clinic
Watertown, South Dakota, 57201
Convenience Care
West Covina, California, 91790
J. Lewis Research/Southwest Family Medicine
West Jordan, Utah, 84084
Ford, Simpson, Lively and Rice Pediatrics
Winston-Salem, North Carolina, 27103
Woburn Pediatric Associates
Woburn, Massachusetts, 01801
United Kingdom22 sites
Cathcart Street Practice
Ayr, KA71BJ
Townhead Surgery
Ayrshire, KA12 0AY
Ashville Medical Center
Barnsely, South Yorks, S703RJ
Stonehill Medical Centre
Bolton, BL49Q2
The Orchard Medical Centre
Bristol, BS15 2NJ
The Staploe Medical Centre
Cambs, CB7 5JD
Avondale Surgery Research
Chesterfield, S404TF
Saltash Health Centre
Cornwall, PL12 4BU
Woodend Health Centre
Coventry, CV2 1XA
Gabels Medical Centre
Coventry, CV6 4DD
Govind Health Cenre
Coventry, Cv66 4DD
Woolwell Medical Centre
Devon Plymouth
The Medical Centre
East Horley, KT246QT
Valleyfield Health Centre
Fife, KY128SJ
Castlemilk Health Centre
Glasgow, G459AW
Kingsway Medical
Glasgow
Layton Medical Centre
Lancs, FY37EN
Greenwood & Sneinton Family Medical Practice
Nottingham, NG37DQ
Landsdowne Road Yaxley
Peterborough, PE7 3JL
Knowle House Surgery
Plymouth, PL5 3JD
Wansford Surgery
Wansford, PE86LP
Sherbourne Medical Centre
Warwick Shire, CV324RA
Belgium9 sites
Sint-Vincentiusziekenhuis Sint-Vincentiusstraat
Antwerp, 2018
Private Practice
Berchem, 2600
UVC Brugmann
Brussels, 1030
AZ-VUB Paediatric Clinic
Brussels, 1090
Private Practice
Drongen, 9031
KUL Dienst Jeugdgezondheidszorg
Leuven, 3000
Private Practice
Schoten, 2900
Private Practice
Tienen, 3300
Private Practice
Wondelgem, 9032
Czechia6 sites
IN Boskovice a. s. Detské oddelení
Boskovice, 680 21
In Boskovice a.s. Detske oddeleni
Boskovice, 680 21
Privantni praxe praktickenho
Lysice, 679 71
Privátní praxe praktického lékare pro deti a dorost Lysice
Lysice, 679 71
Nemocnice s poliklinikou v Moste
Most, 434 64
STOPED s.r.o.
Pilsen, 301 66
Hong Kong5 sites
Department of Pediatrics
Chai Wan
Department of Pediatrics/Adolescent Medicine
Hang Hau
Department of Pediatrics - Paediatrics Unit
Kowloon
Department of Pediatrics/Adolescent Medicine
Lai Chi Kok
Department of Pediactrics
Shatin
Taiwan5 sites
Department of Pediatrics
Changhua, 500
Department of Pediatrics
Taichung, 403
Department of Pediatrics
Taipei, 100
Department of Pediatrics
Taipei, 104
Department of Pediatrics
Taoyuan, 333
South Korea4 sites
Department of Pediatrics
Seoul, 120-752
Dept. of Pediatrics
Seoul, 130-702
Department of Pediatrics
Seoul, 135-230
Department of Pediatrics
Seoul, 152-703
Ireland3 sites
Springhill Surgery
Bangor County, BT 19 1PP
Randalstown Health Centre
Randalsotown, BT413AE
Nottinghill Practice, Whiteabbey Health Centre
Whiteabbey, BT37 9QN
About this study
Official title: A Randomized, Double-Blind Trial to Assess the Safety and Relative Efficacy of CAIV-T Against Inactivated Influenza Vaccine in Children 6-59 Months of Age
The primary objective of this study is to estimate the relative efficacy and assess the safety of CAIV-T compared to TIV.
- Conditions
- Influenza
- Being tested
- Liquid CAIV-T
- Medical subject headings
- Influenza, Human
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Liquid CAIV-TDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary efficacy endpoint of this study is the relative efficacy of CAIV-T
compared to TIV against the incidence of culture-confirmed symptomatic influenza infection caused by community-acquired wild-type strains antigenically similar to those contained in the vaccine, occurring during the
influenza surveillance period and at least 14 days after the last required vaccination
Secondary outcomes (5)
Culture-confirmed symptomatic influenza infection regardless of antigenic match
Febrile acute otitis media (AOM) with antibiotic use associated with culture-confirmed influenza infection antigenically similar to vaccine strains
Febrile acute otitis media (AOM) with antibiotic use associated with culture-confirmed influenza infection regardless of antigenic match
Lower respiratory illness (LRI) with culture-confirmed influenza infection antigenically similar to vaccine strains and
Lower respiratory illness (LRI) with culture-confirmed influenza infection regardless of antigenic match
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2005 (estimated)
- Study startOct 2004
- Study completionDec 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for InfluenzaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind
- Enrolment
- 8,500 participants
Sponsor and investigators
- Lead sponsor
- MedImmune LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Robert Walker, M.D., Study director, MedImmune LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00128167
- Sponsor's protocol ID
- MI-CP111
- Status last verified
- Jul 2006
- First submitted
- 5 Aug 2005
- Last updated
- 13 Sep 2021
- Results posted
- No
Publications
Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007 Feb 15;356(7):685-96. doi: 10.1056/NEJMoa065368.
PubMed 17301299
Study at a glance
From the registry record, last updated by the sponsor on 13 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind Trial to Assess the Safety and Relative Efficacy of CAIV-T Against Inactivated Influenza Vaccine in Children 6-59 Months of Age
- ClinicalTrials.gov ID
- NCT00128167
- Acronym / sponsor ID
- MI-CP111
- Conditions
- Influenza
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 8,500 participants
- Lead sponsor
- MedImmune LLCIndustry (pharma, biotech, devices)
- Study start
- Oct 2004
- Study completion
- Dec 2005
- First posted
- 9 Aug 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to estimate the relative efficacy and assess the safety of CAIV-T compared to TIV.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind
Who may qualify
- Ages
- 6 to 59 months
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- Age 6-59 months of age (not yet reached their 5th birthday)
- Parent or guardian available by telephone
- Available for illness visits at clinic or at home during the influenza surveillance period
- Written informed consent (and Health Insurance Portability and Accountability Act [HIPAA] authorization for U.S. Participants) obtained from the participant's parent or legal guardian and
- Ability of the parent/guardian to understand and comply with the requirements of the protocol
Key exclusion criteria (15 listed)
- History of hypersensitivity to any component of CAIV-T or inactivated influenza vaccine, including egg or egg protein
- History of hypersensitivity to gentamicin
- Any known immunosuppressive condition or immune deficiency disease (including HIV infection), or ongoing receipt of any immunosuppressive therapy
- History of Guillain-Barre syndrome
- Medically-diagnosed wheezing, bronchodilator use, or steroid use (systemic or inhaled) within the previous 42 days by parent report or chart review (e.g., children with recent persistent asthma are excluded), or history of severe asthma
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Liquid CAIV-T | Drug | – |
Primary outcome
The primary efficacy endpoint of this study is the relative efficacy of CAIV-T
compared to TIV against the incidence of culture-confirmed symptomatic influenza infection caused by community-acquired wild-type strains antigenically similar to those contained in the vaccine, occurring during the
influenza surveillance period and at least 14 days after the last required vaccination
5 secondary outcomes
Culture-confirmed symptomatic influenza infection regardless of antigenic match
Febrile acute otitis media (AOM) with antibiotic use associated with culture-confirmed influenza infection antigenically similar to vaccine strains
Febrile acute otitis media (AOM) with antibiotic use associated with culture-confirmed influenza infection regardless of antigenic match
Lower respiratory illness (LRI) with culture-confirmed influenza infection antigenically similar to vaccine strains and
Lower respiratory illness (LRI) with culture-confirmed influenza infection regardless of antigenic match
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Sep 2021.
- Derived from this study: PubMed 17301299Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007 Feb 15;356(7):685-96. doi: 10.1056/NEJMoa065368.
Related trials for Influenza
Active, not recruitingEarly Phase 1
Vaccine Pandemic Preparedness Through Airway Immunology Characterization
Influenza, Human
RecruitingPhase 1
pH1N1 Blinded Challenge Study
Influenza
RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Influenza
RecruitingPhase 2
BPL-1357 Against H1N1 Influenza Virus Challenge
Influenza, Human
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Robert Walker, M.D. study director
MedImmune LLC
161 sites in 8 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Liquid CAIV-T in people with Influenza, run by MedImmune LLC at 161 sites in 8 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 161 sites in United States, United Kingdom, Belgium, Czechia, Hong Kong and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary efficacy endpoint of this study is the relative efficacy of CAIV-T. The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00128167, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Sep 2021; AzTrials last refreshed its copy on 8 Nov 2026.